Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Physical activity and healthcare cost of type 2 diabetic patients seen at basic units of healthcare].

Codogno JS, Fernandes RA, Monteiro HL.

Arq Bras Endocrinol Metabol. 2012 Feb;56(1):6-11. Portuguese.

2.

The burden of physical activity on type 2 diabetes public healthcare expenditures among adults: a retrospective study.

Codogno JS, Fernandes RA, Sarti FM, Freitas Júnior IF, Monteiro HL.

BMC Public Health. 2011 May 4;11:275. doi: 10.1186/1471-2458-11-275.

3.

Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.

Guo JJ, Gibson JT, Gropper DM, Oswald SL, Barker KN.

Am J Manag Care. 1998 Oct;4(10):1433-46.

4.

Physical activity levels of type 2 diabetes patients seen at the outpatient diabetes clinics of two tertiary health institutions in Nigeria.

Adeniyi AF, Fasanmade AA, Aiyegbusi OS, Uloko AE.

Nig Q J Hosp Med. 2010 Oct-Dec;20(4):165-70.

PMID:
21913522
5.

A workplace physical activity program at a public university in Mexico can reduce medical costs associated with type 2 diabetes and hypertension.

Méndez-Hernández P, Dosamantes-Carrasco D, Siani C, Flores YN, Arredondo A, Lumbreras-Delgado I, Granados-García VM, Denova-Gutiérrez E, Gallegos-Carrillo K, Salmerón J.

Salud Publica Mex. 2012 Jan-Feb;54(1):20-7.

7.

Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.

Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V.

J Diabetes Complications. 2007 Mar-Apr;21(2):75-83.

PMID:
17331855
8.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

9.

Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.

Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT.

Clin Ther. 2003 Nov;25(11):2958-71.

PMID:
14693318
10.

Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.

Zhao Y, Ye W, Boye KS, Holcombe JH, Swindle R.

Diabet Med. 2009 Jan;26(1):61-9. doi: 10.1111/j.1464-5491.2008.02616.x.

PMID:
19125762
11.

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.

Pelletier EM, Shim B, Ben-Joseph R, Caro JJ.

Pharmacoeconomics. 2009;27(6):479-90. doi: 10.2165/00019053-200927060-00004.

PMID:
19640011
12.

The cost of treating type 2 diabetes (CODEIRE).

Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S.

Ir Med J. 2006 Nov-Dec;99(10):307-10.

PMID:
17274175
13.

Associations among physical activity, comorbidities, depressive symptoms and health-related quality of life in type 2 diabetes.

Daniele TM, Bruin VM, Oliveira DS, Pompeu CM, Forti AC.

Arq Bras Endocrinol Metabol. 2013 Feb;57(1):44-50.

14.

Cost of Type 2 Diabetes mellitus in Hong Kong Chinese.

Chan BS, Tsang MW, Lee VW, Lee KK.

Int J Clin Pharmacol Ther. 2007 Aug;45(8):455-68.

PMID:
17725179
15.

Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN).

Wolf AM, Siadaty M, Yaeger B, Conaway MR, Crowther JQ, Nadler JL, Bovbjerg VE.

J Am Diet Assoc. 2007 Aug;107(8):1365-73.

PMID:
17659904
16.

Does physical activity reduce seniors' need for healthcare?: a study of 24 281 Canadians.

Woolcott JC, Ashe MC, Miller WC, Shi P, Marra CA; PACC Research Team.

Br J Sports Med. 2010 Sep;44(12):902-4. doi: 10.1136/bjsm.2008.057216. Epub 2009 Oct 23.

PMID:
19854760
17.

[A health promotion programme's effectiveness in reducing medical care costs].

Martínez-López E, Grajales IC.

Rev Salud Publica (Bogota). 2010 Dec;12(6):938-49. Spanish.

18.

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.

Misurski D, Lage MJ, Fabunmi R, Boye KS.

Appl Health Econ Health Policy. 2009;7(4):245-54. doi: 10.2165/11318730-000000000-00000.

PMID:
19905038
19.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
20.

Supplemental Content

Support Center